Sage Therapeutics (SAGE) PT Raised to $85 at Needham & Company; Named Neuroscience Top Pick for 2022
Tweet Send to a Friend
Needham & Company analyst Ami Fadia raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $85.00 (from $79.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
